Akums Drugs and Pharmaceutical Net Assets
Akums Drugs and Pharmaceutical net assets. Based on the latest financial reports, Akums Drugs and Pharmaceutical (AKUMS) has net assets worth Rs33.31 Billion INR (≈ $360.25 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs54.47 Billion ≈ $589.07 Million USD) and total liabilities (Rs21.16 Billion ≈ $228.82 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore AKUMS shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs33.31 Billion |
| % of Total Assets | 61.16% |
| Annual Growth Rate | 51.93% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 137.47 |
Net Assets of Akums Drugs and Pharmaceutical (2022–2026)
Net assets of Akums Drugs and Pharmaceutical from 2022 to 2026. This chart illustrates how Akums Drugs and Pharmaceutical's net assets have evolved over time, based on quarterly financial data. See Akums Drugs and Pharmaceutical (AKUMS) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Akums Drugs and Pharmaceutical (2022–2026)
The table below shows the annual net assets of Akums Drugs and Pharmaceutical from 2022 to 2026. For live market cap and overall valuation, see how much is Akums Drugs and Pharmaceutical worth.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | Rs33.31 Billion ≈ $360.25 Million |
+8.73% |
| 2025-03-31 | Rs30.64 Billion ≈ $331.32 Million |
+325.21% |
| 2024-03-31 | Rs7.20 Billion ≈ $77.92 Million |
-0.40% |
| 2023-03-31 | Rs7.23 Billion ≈ $78.23 Million |
+15.71% |
| 2022-03-31 | Rs6.25 Billion ≈ $67.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Akums Drugs and Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 274.0% over the analyzed period, indicating profitable operations and earnings retention.
Akums Drugs and Pharmaceutical Net Assets Breakdown (March 2026)
Akums Drugs and Pharmaceutical net assets breakdown by equity component as of March 2026.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs20.86 Billion | 62.94% |
| Common Stock | Rs306.21 Million | 0.92% |
| Other Components | Rs11.97 Billion | 36.13% |
| Total Equity | Rs33.13 Billion | 100.00% |
Akums Drugs and Pharmaceutical Competitors by Market Cap
The table below lists competitors of Akums Drugs and Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jiangling Motors Corp Ltd
SHE:000550
|
$1.25 Billion |
|
China Express Airlines Co Ltd Class A
SHE:002928
|
$1.25 Billion |
|
Guild Holdings Co
NYSE:GHLD
|
$1.25 Billion |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
|
$1.25 Billion |
|
Aotecar New Energy Technology Co Ltd
SHE:002239
|
$1.24 Billion |
|
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
|
$1.24 Billion |
|
ATOSS Software SE
F:AOF
|
$1.24 Billion |
|
GMP Property SOCIMI SA
MC:YGMP
|
$1.24 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Akums Drugs and Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 30,470,140,000 to 33,133,480,000, a change of 2,663,340,000 (8.7%).
- Net income of 2,551,880,000 contributed positively to equity growth.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs2.55 Billion | +7.7% |
| Other Changes | Rs111.46 Million | +0.34% |
| Total Change | Rs- | 8.74% |
Book Value vs Market Value Analysis
This analysis compares Akums Drugs and Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.47x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 19.02x to 3.47x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | Rs39.52 | Rs751.50 | x |
| 2023-03-31 | Rs45.57 | Rs751.50 | x |
| 2024-03-31 | Rs45.08 | Rs751.50 | x |
| 2025-03-31 | Rs203.66 | Rs751.50 | x |
| 2026-03-31 | Rs216.44 | Rs751.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Akums Drugs and Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.70%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.85%
- • Asset Turnover: 0.80x
- • Equity Multiplier: 1.64x
- Recent ROE (7.70%) is above the historical average (-1.83%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -40.60% | -6.92% | 1.19x | 4.93x | Rs-3.15 Billion |
| 2023 | 13.23% | 2.73% | 1.06x | 4.55x | Rs231.36 Million |
| 2024 | -0.57% | -0.10% | 1.14x | 4.96x | Rs-749.85 Million |
| 2025 | 11.10% | 8.31% | 0.99x | 1.35x | Rs334.75 Million |
| 2026 | 7.70% | 5.85% | 0.80x | 1.64x | Rs-761.47 Million |
Industry Comparison
This section compares Akums Drugs and Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $32,604,789,550
- Average return on equity (ROE) among peers: 18.60%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Akums Drugs and Pharmaceutical (AKUMS) | Rs33.31 Billion | -40.60% | 0.64x | $1.24 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $328.12 Million | 0.87% | 1.65x | $33.51 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $5.43 Billion | 16.52% | 1.69x | $449.90 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $13.86 Billion | -0.01% | 0.47x | $908.26 Million |
| Abbott India Limited (ABBOTINDIA) | $26.02 Billion | 26.54% | 0.48x | $6.23 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $11.72 Billion | 34.25% | 0.26x | $4.48 Billion |
| Alkem Laboratories Limited (ALKEM) | $63.09 Billion | 17.86% | 0.58x | $6.75 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.16 Billion | 28.39% | 0.27x | $160.43 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $31.90 Billion | 25.98% | 0.88x | $1.93 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $138.92 Billion | 17.02% | 0.90x | $10.61 Billion |
About Akums Drugs and Pharmaceutical
Akums Drugs and Pharmaceuticals Limited manufactures and sells pharmaceutical products and active pharmaceutical ingredients India and internationally. The company provides drugs, ayurvedic, nutraceuticals, food and dietary supplements, derma and cosmetics, healthcare and hospital products, over-the-counter (OTC) products, active pharmaceutical ingredients, excipients, and compounds. It also offe… Read more